APA (7th ed.) Citation

de Botton, S., Brandwein, J. M., Wei, A. H., Pigneux, A., Quesnel, B., Thomas, X., . . . Milkovich, G. (2021). Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Medicine, 10(18), 6336. https://doi.org/10.1002/cam4.4182

Chicago Style (17th ed.) Citation

de Botton, Stéphane, et al. "Improved Survival with Enasidenib Versus Standard of Care in Relapsed/refractory Acute Myeloid Leukemia Associated with IDH2 Mutations Using Historical Data and Propensity Score Matching Analysis." Cancer Medicine 10, no. 18 (2021): 6336. https://doi.org/10.1002/cam4.4182.

MLA (9th ed.) Citation

de Botton, Stéphane, et al. "Improved Survival with Enasidenib Versus Standard of Care in Relapsed/refractory Acute Myeloid Leukemia Associated with IDH2 Mutations Using Historical Data and Propensity Score Matching Analysis." Cancer Medicine, vol. 10, no. 18, 2021, p. 6336, https://doi.org/10.1002/cam4.4182.